Dr. Reddy's announces launch of new generics for U.S. market

HYDERABAD, India Dr. Reddy's Labs, an Indian generic drug maker, announced Thursday that it has several new products on their way to U.S. consumers, with five Food and Drug Administration regulatory approvals and new product launches set for the U.S. market.

The new drugs are levetiracetam tablets, a generic version of UCB's epilepsy drug Keppra, which IMS Health reports as having annual sales of $1.1 billion; omeprazole capsules, a generic version of AstraZeneca's gastro-esophageal reflux disease drug Prilosec DR, which has sales of $168 million; lamotragine CD chewable tablets, a generic version of GlaxoSmithKline's epilepsy drug Lamictal, which has sales of $87 million, and lamotrigine swallowed tablets, which have sales of $2.3 billion; and divalproex capsules and delayed-release pellets, a generic version of Abbott's epilepsy and bipolar disorder drug Depakote, which has sales of $126 million.